Jessica M Conway
Overview
Explore the profile of Jessica M Conway including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phan T, Conway J, Pagane N, Kreig J, Sambaturu N, Iyaniwura S, et al.
PLoS Pathog
. 2024 Jul;
20(7):e1012236.
PMID: 39074163
Most people living with HIV-1 experience rapid viral rebound once antiretroviral therapy is interrupted; however, a small fraction remain in viral remission for an extended duration. Understanding the factors that...
2.
Mainou E, Berendam S, Obregon-Perko V, Uffman E, Phan C, Shaw G, et al.
Epidemics
. 2024 Jul;
48:100780.
PMID: 38964130
While the benefits of early antiretroviral therapy (ART) initiation in perinatally infected infants are well documented, early initiation is not always possible in postnatal pediatric HIV infections. The timing of...
3.
Mainou E, Berendam S, Obregon-Perko V, Uffman E, Phan C, Shaw G, et al.
bioRxiv
. 2024 Jun;
PMID: 38895223
The presence of antibodies against HIV in infected children is associated with a greater capacity to control viremia in the absence of therapy. While the benefits of early antiretroviral treatment...
4.
Mainou E, Ribeiro R, Conway J
PLoS Comput Biol
. 2024 Jun;
20(6):e1012129.
PMID: 38848426
Understanding the dynamics of acute HIV infection can offer valuable insights into the early stages of viral behavior, potentially helping uncover various aspects of HIV pathogenesis. The standard viral dynamics...
5.
Mainou E, Berendam S, Obregon-Perko V, Uffman E, Phan C, Shaw G, et al.
bioRxiv
. 2024 Jun;
PMID: 38826467
Viral dynamics of acute HIV infection and HIV rebound following suspension of antiretroviral therapy may be qualitatively similar but must differ given, for one, development of adaptive immune responses. Understanding...
6.
Ciupe S, Conway J
Microorganisms
. 2024 May;
12(5).
PMID: 38792730
In-host models have been essential for understanding the dynamics of virus infection inside an infected individual. When used together with biological data, they provide insight into viral life cycle, intracellular...
7.
Phan T, Conway J, Pagane N, Kreig J, Sambaturu N, Iyaniwura S, et al.
bioRxiv
. 2024 May;
PMID: 38746144
Most people living with HIV-1 experience rapid viral rebound once antiretroviral therapy is interrupted; however, a small fraction remain in viral remission for an extended duration. Understanding the factors that...
8.
Mainou E, Berendam S, Obregon-Perko V, Uffman E, Phan C, Shaw G, et al.
bioRxiv
. 2023 Jul;
PMID: 37502921
While the benefits of early antiretroviral therapy (ART) initiation in perinatally infected infants are well documented, early ART initiation is not always possible in postnatal pediatric HIV infections, which account...
9.
Conway J, Abel Zur Wiesch P
Pharmaceutics
. 2021 Aug;
13(8).
PMID: 34452142
The antiviral remdesivir has been approved by regulatory bodies such as the European Medicines Agency (EMA) and the US Food and Drug administration (FDA) for the treatment of COVID-19. However,...
10.
Regan J, Flynn J, Rosenthal A, Jordan H, Li Y, Chishti R, et al.
Open Forum Infect Dis
. 2021 Aug;
8(8):ofab153.
PMID: 34430669
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) kinetics remain understudied, including the impact of remdesivir. In hospitalized individuals, peak sputum viral load occurred in week 2 of symptoms, whereas viremia...